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Introduction
　Human CD93 is a heavily O -glycosylated type I 
transmembrane glycoprotein consisting of unique C-type 
lectin domains (CTLDs) 1,2). CD93 is mainly expressed on 
m y e l o i d c e l l s  ( m o n o c y t e s a n d g r a n u l o c y t e s ) , 
hematopoietic stem cells and endothelial cells3-5). In 
addit ion, CD93 is a lso co-expressed on naive T 
lymphocytes (CD4+CD45RA+cells) of neonatal umbilical 
cord blood cells (UCBCs), but not on normal adult 
peripheral blood cells (PBCs)6). In terms of the biological 
functions, CD93 reportedly plays a critical role in the 
c learance/exclusion of apoptotic cel ls 7,8) and in 
angiogenesis9).
　On the other hand, soluble-form CD93 (sCD93) has also 
been detected in the human serum/plasma of normal 
adults10). Furthermore, the sCD93 levels in the neonatal 
umbilical cord blood (UCB) have been shown to be 
significantly higher than those in normal adult peripheral 
blood (PB)11),12）. Meanwhile, cell surface CD93 is also 
reportedly shed from activated human myeloid cells 
(monocytes and neutrophils) in the form of sCD93. In 
particular, sCD93 shedding/release was detected in vitro 
(culture supernatant) in response to treatment with 
lipopolysaccharide (LPS), tumor necrosis factor (TNF)-α 
and phorbol 12-myristate 13-acetate (PMA), the protein 
kinase C (PKC) activator10-12).
　As described above, although CD93 is a physiologically 
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Abstract
 In this study, we examined the secretion of soluble-form CD93 (sCD93) from human endothelial progenitor 
cells (HEPCs) expressing cell surface CD93 by enzyme-linked immunoassay (EIA) using CD93 monoclonal 
antibody (mAb) (mNI-11) established in our laboratories. We found that a small amount of sCD93 was 
spontaneously secreted into the culture supernatants of HEPCs. Furthermore, significantly (P < 0.01) 
enhanced secretion of sCD93 was found in the culture supernatants of HEPCs treated with phorbol 
12-myristate 13-acetate (PMA), a protein kinase C (PKC) activator, which was significantly (P < 0.01) 
suppressed by treatment of the cells with the protein kinase (PKC) inhibitor Go6976. Interestingly, 
depolymerization of the actin filaments in the cells by cytochalasin E (CyE) also significantly (P < 0.01) 
enhanced the sCD93 secretion into the culture supernatants of HEPCs. Taken together, these findings 
suggest that the sCD93 might serve as a new biomarker for analyzing the biological and immunological 
functions of HEPCs.
Key words : cytochalasin E, human endothelial progenitor cells, phorbol 12-myristate 13-acetate, 
soluble-form CD93 molecule.
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Analysis of HEPCs treated/not treated with 
various substances
　HEPCs (2 x 105 cells/mL) in growth medium (4 mL) 
were seeded in culture flasks (Sumitomo Co., Tokyo) and 
treated/not treated with PMA (100 ng/mL) in the 
presence or absence of the conventional protein kinase C 
(cPKC) inhibitor, Go6976 (3.0 μM), for 6 hrs, 10 hrs or 24 
hrs in a CO2 incubator. In an additional experiment, the 
HEPCs were treated or not treated with cytochalasin E 
(CyE), a drug that causes actin filament depolymerization 
(100 ng/mL) under the same conditions. The culture 
supernatants were collected and analyzed for the 
presence of soluble-form CD93 (sCD93) by an originally 
constructed enzyme-linked immunoassay (EIA) system. 
On the other hand, the morphological changes of the 
HEPCs treated or not treated with the aforementioned 
substances were also observed and photos were taken 
under a phase-contrast microscope.
Flow cytometry
　The HEPCs were washed in cold phosphate-buffered 
saline (PBS) containing 0.1% NaN3 (hereinafter referred 
to as the washing buffer) and incubated in washing buffer 
containing 25% normal goat serum and 1 mg/mL of 
normal human IgG for 10 min on ice, to block the Fc 
receptor for IgG. The cells were then incubated with an 
optimal concentration of PE-conjugated CD93 mAb 
(mNI-11), FITC-conjugated CD34 mAb (My10), FITC-
conjugated CD146 mAb (541-10B2) or PE-conjugated 
CD49d mAb (BU49) for 40 min at room temperature. A 
negative control (NC) was set by incubation of the cells 
with mixed PE-conjugated and FITC-conjugated isotype-
matched normal mouse IgG1 under the same conditions. 
Following a final wash with the washing buffer, the 
cellular debris was excluded. Thereafter, the percentages 
of positively stained cells for each mAb were determined 
as single-color f low-cytometric profi les using a 
fluorescence activated cell sorter (FACScan) (Becton 
Dickinson Co.). The percentages of cells showing 
positive staining for each of the mAbs were calculated 
for each FACS profile. The experiment was carried out 
in triplicate.
and immunologically important and unique molecule in 
immune regulation, the patterns and levels of sCD93 
secretion from human endothelial progenitor cells 
(HEPCs) remain very poorly understood.
　In this study, we investigated the secretion levels of 
sCD93 from HEPCs in response to treatment with 
several substances such as a PMA and cytochalasin 
E (CyE), a drug that causes actin filament depolymerization, 
by an enzyme-linked immunoassay (EIA) using CD93 
monoclonal antibody (mAb) (mNI-11)3,6,12,13) established in 
our laboratories.
Materials and Methods
Antibodies and reagents
　Phycoerythrin (PE)-conjugated or non-conjugated 
CD93 monoclonal antibody (mAb) (mNI-11) (mouse 
IgG1)3,6,12,13) was established in our laboratories. A biotin-
c o n j u g a t e d C D93  m A b , X -2  ( m o u s e I g G1 ) ,  a n d 
h o r s e r a d i s h p e r o x i d a s e ( H R P O D ) - c o n j u g a t e d 
streptavidin were purchased from Cosmo Bio Co. (Tokyo, 
Japan). Fluorescein isothiocyanate (FITC)-conjugated 
CD34 mAb (My10) (mouse IgG1) was purchased from BD 
Biosciences Co. (U.S.A.). PE-conjugated CD49d mAb 
(BU49) (mouse IgG1) was purchased from Ancell Co. 
(U.S.A.). An FITC-conjugated CD146 mAb (541-10B2) 
(mouse IgG1) was purchased from Miltenyi Biotec Co. 
(U.S.A.). PE-conjugated or FITC-conjugated isotype-
matched normal mouse IgG1 was purchased from MBL 
Co. (Nagoya, Japan). Phorbol 12-myristate 13-acetate 
(PMA) and a conventional protein kinase C (cPKC) 
inhibitor (Go6976) were purchased from Cosmo Bio Co. 
(Tokyo, Japan). Cytochalasin E (CyE) was purchased from 
Sigma Co. (U.S.A.).
Human endothelial progenitor cells (HEPCs)
　Cryopreserved human endothelial progenitor cells 
(HEPCs) (Z7030001) and growth medium (Z7030003) were 
obtained from BCH Co. (U.S.A.). The HEPCs were 
cultured in the growth medium, according to a routine 
protocol.
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system. As shown in Figure 1, CD93 (82.4%), CD34 
(18.9%) and CD146 (99.3%) were expressed on the HEPCs, 
while no expression of CD49d (0.9%) was found on the 
cells. These findings suggest that the HEPCs used in this 
study had the properties of progenitor-related cells.
　Next, we investigated the amounts of soluble-form 
CD93 (sCD93) secreted by the HEPCs treated or not 
treated with PMA at 6 hrs, 10 hrs, and 24 hrs, by an 
originally constructed EIA system using a CD93 mAb 
(mNI-11). As shown in Figure 2, a small amount of sCD93 
was spontaneously secreted by the HEPCs into the 
culture supernatants at 6 hrs (7.7 ng/mL, on average), 10 
hrs (9.5 ng/mL, on average), and 24 hrs (9.6 ng/mL, on 
average) in the absence of PMA treatment. On the other 
hand, strongly enhanced secretion of sCD93 was found at 
6 hrs (21.5 ng/mL, on average), 10 hrs (24.8 ng/mL, on 
average), and 24 hrs (34.5 ng/mL, on average) in the 
culture supernatants of the HEPCs treated with PMA. 
These data indicate that secretion of sCD93 was 
significantly enhanced by PMA treatment even from an 
early phase (6 hrs), and that PMA treatment significantly 
(P < 0.01) enhanced the amount of sCD93 secreted by the 
HEPCs into the culture supernatants of HEPCs as 
compared to the amount secreted by the control HEPCs 
(not treated with PMA). Furthermore, the amounts of 
sCD93 secreted into the culture supernatants by the 
HEPCs treated with PMA in the presence of the 
conventional protein kinase C (cPKC) inhibitor Go6976 
(3.0 μM) were 11.5 ng/mL, on average, at 6 hrs, 12.6 ng/
mL, on average, at 10 hrs, 16.2 ng/mL, on average, at 24 
hrs (Fig. 2); namely, the enhanced secretion of sCD93 by 
the HEPCs induced by PMA was significantly (P < 0.01) 
suppressed by concomitant treatment of the cells with 
Go6976. Figure 4 shows the morphological changes of 
the HEPCs in the presence of PMA.
　As described above, human CD93 has a molecular 
w e i g h t  o f  a b o u t  90 -100  k D a a n d i s  a  h e a v i l y 
O-glycosylated type I transmembrane protein1,2) that is 
main ly expressed on monocytes , g ranulocytes 
(neutrophils), endothelial cells, and CD34+ hematopoietic 
stem cells)3-6,12). Furthermore, we also found strong 
expression of CD93 on the HEPCs in this study. Thus, 
CD93 may be regarded as a very unique and important 
molecule in the regulation of various human immune 
responses.
Detection of soluble-form CD93 (sCD93)
　EIA plates (Sumitomo Co., Tokyo) were coated with 
500 ng/mL of CD93 mAb (mNI-11) in carbonate-
bicarbonate buffer (0.01M NaCO3, 0.035M NaHCO3, 
pH9.6) for 24 hrs at 4° C. The wells were washed four 
times with PBS containing 0.05% Tween-20 (PBST) and 
blocked with PBST containing 2% BSA (BSA-PBST) for 
60 min at room temperature. Thereafter, the wells were 
washed three times with PBST. Culture supernatants (x2 
dilution with 0.1% BSA-PBST; 50 μL) and biotin-labeled 
CD93 mAb (X-2) (x2,500 dilution with 0.1% BSA-PBST; 50 
μL) were then added to each well , fol lowed by 
incubation for 60 min at room temperature with shaking. 
A recombinant protein of the CD93 molecule (TP306980) 
(Origene Technologies, Inc.) was added to each well as a 
positive control or as a CD93-standard. The wells were 
washed eight times with PBST and HRPOD-conjugated 
streptavidin (x5,000 dilution with 0.1% BSA-PBST; 100 
μL) was added to each well, followed by incubation for 
30 min at room temperature with shaking. The wells 
were then washed 10 t imes with PBST, and the 
substrate-chromogen (TMB; Cosmo Bio Co.; 100 μL) 
was added to each well, followed by incubation for 10 min 
at room temperature with gentle shaking. The reaction 
was stopped by the addition of 0.5N-HCl (100 μL), and 
the optical density (O.D.) was read at 450 nm using a 
multichannel EIA-microplate reader (TOSOH Co.). The 
experiment was repeated five times.
Statistical analysis
　Data are expressed as mean ± standard deviation (SD). 
The statistical analysis was performed using an unpaired 
Student t-test. Differences at P < 0.01 were considered 
to be significant.
Results and Discussion
　First of all, we investigated the expressions of CD93 
(hematopoietic progenitor/endothelial cell marker), 
CD34 (hematopoiet ic stem cel l marker ) , CD146 
(endothelial cell marker) and CD49d (α4 integrin marker) 
on the HEPCs using a single-color flow-cytometric 
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antigen- and mitogen-induced proliferation of human T 
cel ls . For example, when added to T cel ls , low 
concentrations of cytochalasins dramatically enhance 
DNA synthesis as mitogens, resulting in increases of the 
cyclic AMP (cAMP) and intracellular Ca2+ concentrations 
and phosphorylation of some kinases such as protein 
kinase A (PKA), protein kinase C (PKC), and protein 
tyrosine kinase (PTK)19). We reported previously that CyE 
strongly induced low-affinity Fcε receptor II (CD23) 
expression on the human monocyte-like cell line, U93720) 
and expression of the intercellular adhesion molecule-
1(ICAM-1) (CD54) on the HeLa epithelial cell line21). These 
findings indicate that depolymerization of microfilament 
systems is closely involved in various immunoregulatory 
mechanisms. Thus, we considered that the enhanced 
secretion of sCD93 following treatment with CyE may be 
closely associated with the depolymerization of the 
microfilament systems induced by the compound.
　In conclusion, we found, for the first time, that PMA 
and CyE treatment strongly induce the secretion of 
sCD93 from HEPCs. Further analyses are necessary for 
understanding the detailed intracellular mechanism(s) of 
sCD93 secretion from HEPCs at the molecular level.
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Figure 2.  Detection of sCD93 secretion from HEPCs treated or not treated with PMA (100 ng/mL) in the presence or absence of an 
optimal concentration of a PKC inhibitor (Go6976). The amounts of sCD93 in the culture supernatants of the HEPCs after 6 hrs, 10 
hrs and 24 hrs were detected using an EIA system (See Materials and Methods for details). Data are expressed as mean ± SD. The 
analysis was repeated in triplicate per sample. The experiment was repeated four times. *P < 0.01 (PMA vs. Control). ** P < 0.01 
(PMA vs. PMA+Go6976 ).
Figure 1.  Expression patterns of CD93, CD34, CD146 and CD49d on the HEPCs. The HEPCs were incubated with PE-conjugated 
CD93 mAb (mNI-11) (panel B), FITC-conjugated CD34 mAb (My10) (panel C), FITC-conjugated CD146 mAb (541-10B2) (panel D) or 
PE-conjugated CD49d mAb (BU49) (panel E) for 40 min at room temperature. The percentages of positively stained cells for each of 
the mAbs were analyzed using a single-color flow-cytometric system (See Materials and Methods for details). Percentages are 
expressed in each panel. Negative control (NC) (panel A) was incubated with mixed PE-conjugated and FITC-conjugated isotype-
matched normal mouse IgG1. The arrows within the each panel indicate the analyzed population. The analysis was repeated in 
triplicate per sample. The experiment was repeated three times.
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Figure 3.  Detection of sCD93 secretion from HEPCs treated or not treated with CyE (100 ng/mL). The amounts of sCD93 in the 
culture supernatants of the HEPCs after 6 hrs, 10 hrs and 24 hrs were detected using an EIA system (See Materials and Methods 
for details). Data are expressed as mean ± SD. The analysis was repeated in triplicate per sample. The experiment was repeated 
three times. *P < 0.01 (CyE vs. Control).
Figure 4.  Morphological changes of the HEPCs treated or not treated with PMA or CyE) after 24 hrs (see Materials and Methods 
for details). The morphological changes of the HEPCs were observed by phase-contrast microscopy (100x). A: control (treated 
without substance), B: treated with PMA (100 ng/mL), C: treated with PMA (200 ng/mL), D: treated with CyE (100 ng/mL).
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要　旨
　ヒト血管内皮前駆細胞（Human endothelial progenitor cells :HEPCs）から分泌される可溶性 CD93
（sCD93）分子の動態を自主開発した抗ヒト CD93 抗体（mNI-11）を用いて解析した。HEPCs は低濃度で
あるが、sCD93 分子を培養液中に自然分泌していることがわかった。HEPCs を PKC 活性剤である PMA
で処理したところ、sCD93 分子の分泌は有意に増強した（P < 0.01）。また、PMA 処理の初期段階から
sCD93 分泌の増強は認められた。次に、PMA 処理 HEPCs に PKC 活性阻害剤である Go6976 を添加した
ところ、sCD93 分子の分泌は有意に抑制された（P < 0.01）。一方、HEPCs をアクチンフィラメントの脱
重合剤（サイトカラシン E）で処理したところ、sCD93 分子の分泌が有意に増強した（P < 0.01）。
HEPCs から分泌される sCD93 分子は、PKC によるリン酸化とアクチンフィラメントの脱重合が密接に関
与していることがわかった。。
キーワード：サイトカラシン E、ヒト血管内皮前駆細胞、ホルボールミリステートアセテート、
　　　　　　可溶性 CD93 分子
九州保健福祉大学研究紀要  16 :  121 〜 128, 2015
